Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Centessa Pharmaceuticals (CNTA) Shares Outstanding (2021 - 2026)

Centessa Pharmaceuticals has reported Shares Outstanding over the past 5 years, most recently at $149.2 million for Q4 2025.

  • Quarterly Shares Outstanding rose 12.51% to $149.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $149.2 million through Dec 2025, up 12.51% year-over-year, with the annual reading at $149.2 million for FY2025, 12.51% up from the prior year.
  • Shares Outstanding was $149.2 million for Q4 2025 at Centessa Pharmaceuticals, up from $134.4 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $149.2 million in Q4 2025 and troughed at $90.0 million in Q4 2021.
  • The 5-year median for Shares Outstanding is $98.8 million (2023), against an average of $110.8 million.
  • Year-over-year, Shares Outstanding increased 1.09% in 2023 and then skyrocketed 34.94% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $90.0 million in 2021, then rose by 5.4% to $94.8 million in 2022, then rose by 4.15% to $98.8 million in 2023, then surged by 34.28% to $132.6 million in 2024, then rose by 12.51% to $149.2 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Shares Outstanding are $149.2 million (Q4 2025), $134.4 million (Q3 2025), and $133.9 million (Q2 2025).